A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia
暂无分享,去创建一个
R. Moriggl | V. Sexl | R. Grausenburger | B. Maurer | S. Kollmann | A. Witalisz-Siepracka | K. Klein | D. Gotthardt | J. Trifinopoulos | Julia List | Angela Hiesinger | Jonatan Kendler | Mehak Rhandawa | Thomas Rülicke | Wencke Walter | Gregor Hoermann
[1] Mengsu Yang,et al. The versatile roles of testrapanins in cancer from intracellular signaling to cell–cell communication: cell membrane proteins without ligands , 2023, Cell & Bioscience.
[2] C. Pirker,et al. Blocking STAT3/5 through direct or upstream kinase targeting in leukemic cutaneous T‐cell lymphoma , 2022, EMBO molecular medicine.
[3] Vasco M. Barreto,et al. Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia , 2022, Leukemia.
[4] Ahmed M. Shawky,et al. A Comprehensive Overview of Globally Approved JAK Inhibitors , 2022, Pharmaceutics.
[5] Shondra M. Pruett-Miller,et al. CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk , 2022, Nature Genetics.
[6] P. Porcu,et al. Cytokines in the Pathogenesis of Large Granular Lymphocytic Leukemia , 2022, Frontiers in Oncology.
[7] Hai Deng,et al. Interleukin-7 Biology and Its Effects on Immune Cells: Mediator of Generation, Differentiation, Survival, and Homeostasis , 2021, Frontiers in Immunology.
[8] R. Moriggl,et al. A STAT5B-CD9 axis determines self-renewal in hematopoietic and leukemic stem cells. , 2021, Blood.
[9] Joseph C. Sun,et al. Deconvoluting global cytokine signaling networks in natural killer cells , 2021, Nature Immunology.
[10] S. Mustjoki,et al. Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells. , 2021, Blood advances.
[11] T. Haferlach,et al. Whole transcriptome sequencing detects a large number of novel fusion transcripts in patients with AML and MDS. , 2020, Blood advances.
[12] Siba El Hussein,et al. Aggressive NK Cell Leukemia: Current State of the Art , 2020, Cancers.
[13] B. Stanger,et al. How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy , 2020, Cancer Research.
[14] S. Bortoluzzi,et al. A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells , 2020, Blood Cancer Journal.
[15] J. Orange,et al. Human STAT5b mutation causes dysregulated human natural killer cell maturation and impaired lytic function. , 2020, The Journal of allergy and clinical immunology.
[16] R. Moriggl,et al. Direct Targeting Options for STAT3 and STAT5 in Cancer , 2019, Cancers.
[17] V. Sexl,et al. STAT5A and STAT5B—Twins with Different Personalities in Hematopoiesis and Leukemia , 2019, Cancers.
[18] K. Ruchalski,et al. Primary intestinal NK-cell lymphoma, EBV-negative: A case report and literature review , 2019, Human Pathology: Case Reports.
[19] R. Moriggl,et al. STAT5BN642H drives transformation of NKT cells: a novel mouse model for CD56+ T-LGL leukemia , 2019, Leukemia.
[20] K. Patel,et al. Chronic lymphoproliferative disorder of NK‐cells: A single‐institution review with emphasis on relative utility of multimodality diagnostic tools , 2018, European journal of haematology.
[21] E. Matutes. The 2017 WHO update on mature T‐ and natural killer (NK) cell neoplasms , 2018, International journal of laboratory hematology.
[22] V. Devita,et al. Conflict of Interest Disclosures , 2018, Global spine journal.
[23] W. Chan,et al. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target , 2018, Nature Communications.
[24] C. Bock,et al. STAT5BN642H is a driver mutation for T cell neoplasia , 2017, The Journal of clinical investigation.
[25] Shaoping Ling,et al. Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes , 2017, Blood Cancer Journal.
[26] Ding Ma,et al. Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia , 2017, Cell Research.
[27] L. Hennighausen,et al. Subset- and tissue-defined STAT5 thresholds control homeostasis and function of innate lymphoid cells , 2017, The Journal of experimental medicine.
[28] Z. Tian,et al. Developmental and Functional Control of Natural Killer Cells by Cytokines , 2017, Front. Immunol..
[29] C. Ong,et al. Oncogenic activation of STAT3 pathway drives PD-L1 expression in natural killer/T cell lymphoma. , 2017 .
[30] T. Waldmann,et al. Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy. , 2017, Annual review of immunology.
[31] D. Dunson,et al. The Genetic Basis of Hepatosplenic T-cell Lymphoma. , 2017, Cancer discovery.
[32] T. Loughran,et al. LGL leukemia: from pathogenesis to treatment. , 2017, Blood.
[33] S. Bortoluzzi,et al. High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. , 2016, Blood.
[34] S. Durum,et al. Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment. , 2016, Blood.
[35] Can Küçük,et al. Clinicopathologic Characterization of Aggressive Natural Killer Cell Leukemia Involving Different Tissue Sites , 2016, The American journal of surgical pathology.
[36] V. Hwa. STAT5B deficiency: Impacts on human growth and immunity. , 2016, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.
[37] John J Murphy,et al. STAT5 in Cancer and Immunity. , 2016, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[38] L. Hennighausen,et al. Signal transducer and activator of transcription 5 (STAT5) paralog dose governs T cell effector and regulatory functions , 2016, eLife.
[39] Z. Bago-Horvath,et al. STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion. , 2016, Cancer discovery.
[40] Sina Hadi Sohi,et al. BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis , 2015, Nucleic Acids Res..
[41] J. Byrd,et al. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK–STAT pathway in Sézary syndrome , 2015, Nature Communications.
[42] J. Snowden,et al. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours , 2015, British Journal of Cancer.
[43] T. Torgerson,et al. Long-Term Follow-up of STAT5B Deficiency in Three Argentinian Patients: Clinical and Immunological Features , 2015, Journal of Clinical Immunology.
[44] Can Alkan,et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells , 2015, Nature Communications.
[45] A. Look,et al. Targeting oncogenic interleukin‐7 receptor signalling with N‐acetylcysteine in T cell acute lymphoblastic leukaemia , 2015, British journal of haematology.
[46] R. Houot,et al. Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] T. Rausch,et al. The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse , 2014, Haematologica.
[48] R. Moriggl,et al. Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia , 2014, Oncotarget.
[49] K. Elenitoba-Johnson,et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. , 2014, Blood.
[50] T. Waldmann,et al. Frequent STAT5B mutations in γδ hepatosplenic T-cell lymphomas , 2014, Leukemia.
[51] S. Mustjoki,et al. Uncovering the pathogenesis of large granular lymphocytic leukemia—novel STAT3 and STAT5b mutations , 2014, Annals of medicine.
[52] O. Lohi,et al. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia , 2014, Leukemia.
[53] S. Mustjoki,et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. , 2013, Blood.
[54] Kari Christine Nadeau,et al. The STAT5b Pathway Defect and Autoimmunity , 2012, Front. Immun..
[55] I. Wistuba,et al. STAT5A-Mediated SOCS2 Expression Regulates Jak2 and STAT3 Activity Following c-Src Inhibition in Head and Neck Squamous Carcinoma , 2011, Clinical Cancer Research.
[56] E. Casanova,et al. A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. , 2011, Blood.
[57] M. Caligiuri,et al. A novel mouse model for the aggressive variant of NK cell and T cell large granular lymphocyte leukemia. , 2010, Leukemia research.
[58] O. Kildahl‐Andersen. [Large granular lymphocyte leukemia]. , 2009, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.
[59] Eric Vivier,et al. Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46 , 2007, Proceedings of the National Academy of Sciences.
[60] A. Belgorosky,et al. Characterization of Immunodeficiency in a Patient With Growth Hormone Insensitivity Secondary to a Novel STAT5b Gene Mutation , 2006, Pediatrics.
[61] Hua Yu,et al. The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.
[62] F. E. Bertrand,et al. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis , 2004, Leukemia.
[63] B. Little,et al. Growth hormone insensitivity associated with a STAT5b mutation. , 2003, The New England journal of medicine.
[64] M. Caligiuri,et al. Fatal Leukemia in Interleukin 15 Transgenic Mice Follows Early Expansions in Natural Killer and Memory Phenotype Cd8+ T Cells , 2001, The Journal of experimental medicine.
[65] W. Leonard,et al. Stat5b Is Essential for Natural Killer Cell–mediated Proliferation and Cytolytic Activity , 1998, The Journal of experimental medicine.
[66] E. Jaffe,et al. EBV-negative Aggressive NK-cell Leukemia/Lymphoma: Clinical, Pathologic, and Genetic Features , 2017, The American journal of surgical pathology.
[67] A. Freud,et al. Fatal leukemia in interleukin-15 transgenic mice. , 2001, Blood cells, molecules & diseases.